Briefing
Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer.
A prospective cohort of 100 people with stage II or III resectable gastric cancer collected tumor and perioperative plasma to test whether ctDNA after adjuvant chemotherapy predicted recurrence. The abstract does not name the assay.
- Design: Evidence level 2
- Assay: Not named in the abstract